Cannabinoids in multiple sclerosis treatment Review article
Article Sidebar
Published:
Mar 31, 2017
Keywords:
multiple sclerosis, cannabinoids
Main Article Content
Abstract
For several years ongoing studies to assess the medical use of cannabinoids are conducted. At the moment some representatives of cannabinoids are approved by FDA for example to reduce spasticity in multiple sclerosis (nabiximol which is a mixture of tetrahydrocannabinol and cannabidiol). Other indications include the treatment of cancer pain (particularly neuropathic pain) in patients who developed resistance to opioids (dronabinol, nabinol, nabiximol) and the treatment of wasting syndrome in AIDS (dronabinol), and alleviation of nausea and vomiting induced by chemotherapy (dronabinol).
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. MS society group: Spasticity, mobility problems and multiple sclerosis [online].
2. Chou R., Peterson K., Helfand M.: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom. Manage. 2004; 28(2): 140-175.
3. Novotna A., Mares J., Ratcliffe S. et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011; 18(9): 1122-1131.
4. Członkowska A., Mirowska-Guzel D.: Choroby wewnętrzne. Stan wiedzy na rok 2010. Rozdział IX: Wybrane choroby układu nerwowego. Medycyna Praktyczna, Kraków 2010: 1971.
5. Fox P., Bain P.G., Glickman S. et al.: The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62(7): 1105-1109.
6. NICE. Spasticity in under 19s: management [online].
7. Wells D.L., Ott C.A.: The “new” marijuana. Ann. Pharmacother. 2011; 45: 414-417.
8. Ashton J.C.: Synthetic cannabinoids as drugs of abuse. Curr. Drug Abuse Rev. 2012; 5: 158-168.
9. Hoyte C.O., Jacob J., Monte A.A. et al.: A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012; 60: 435-438.
10. Kannabinoidy. W: Rang H.P., Dale M.M., Ritter J.M. (red.): Farmakologia. Elsevier Urban & Partner, Wrocław 2014: 226-231.
11. Osei-Hyiaman D., Harvey-White J., Bátkai S. et al.: The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes. (Lond.) 2006; 30(supl. 1): 33-38.
12. Begg M., Pacher P., Bátkai S. et al.: Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005; 106(2): 133-145.
13. Abadinsky H.: Drugs: An Introduction. Wyd. 5. 2004: 62-77; 160-166.
14. Pertwee R.G.: The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 2006; 30: 13-18.
15. Hill K.P.: Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA 2015; 313: 2474-2483.
16. Ablin J., Ste-Marie P.A., Schafer M. et al.: Medical use of cannabis products. Lessons to be learned from Israel and Canada. Schmerz 2016; 30: 3-13.
17. Koppel B.S., Brust J.C., Fife T. et al.: Systematic review efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 2014; 82: 1556-1563.
18. Lohr L.: Chemotherapy-induced nausea and vomiting. Cancer J. 2008; 14(2): 85-93.
19. AOTM. Sativex - stwardnienie rozsiane [online].
20. EMA. Sativex [online].
21. Talan J.: Cannabidiol research of first hope for seizure disorders. Neurology Today 2017; 17(2): 1-10.
22. Zajicek J.P., Hobart J.C., Slade A. et al.; MUSEC Research Group: Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatry 2012; 83(11): 1125-1132.
23. Zajicek J., Fox P., Sanders H. et al.; UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-1526.
24. Zajicek J., Ball S., Wright D. et al.; CUPID investigator group: Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12(9): 857-865.
25. Rog D.J., Nurmikko T.J., Friede T. et al.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-819.
26. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253-258.
27. Whiting P.F., Wolff R.F., Deshpande S. et al.: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 2015; 313: 2456-2473.
28. Farrar J.T., Troxel A.B., Stott C. et al.: Validity, Reliability, and Clinical Importance of Change in a 0–10 Numeric Rating Scale Measure of Spasticity: a Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Clin. Ther. 2008; 30(5): 974-985.
29. Anwar K., Barnes M.P.: A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009; 24(4): 333-340.
30. Hawker G.A., Mian S., Kendzerska T. et al.: Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. (Hoboken) 2011; 63(supl. 11): S240-S252.
31. Wade D.T., Makela P.M., House H. et al.: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 2006; 12(5): 639-645.
32. Nie ma leczniczej marihuany. Medexpress [online].
2. Chou R., Peterson K., Helfand M.: Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom. Manage. 2004; 28(2): 140-175.
3. Novotna A., Mares J., Ratcliffe S. et al.: A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011; 18(9): 1122-1131.
4. Członkowska A., Mirowska-Guzel D.: Choroby wewnętrzne. Stan wiedzy na rok 2010. Rozdział IX: Wybrane choroby układu nerwowego. Medycyna Praktyczna, Kraków 2010: 1971.
5. Fox P., Bain P.G., Glickman S. et al.: The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62(7): 1105-1109.
6. NICE. Spasticity in under 19s: management [online].
7. Wells D.L., Ott C.A.: The “new” marijuana. Ann. Pharmacother. 2011; 45: 414-417.
8. Ashton J.C.: Synthetic cannabinoids as drugs of abuse. Curr. Drug Abuse Rev. 2012; 5: 158-168.
9. Hoyte C.O., Jacob J., Monte A.A. et al.: A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann. Emerg. Med. 2012; 60: 435-438.
10. Kannabinoidy. W: Rang H.P., Dale M.M., Ritter J.M. (red.): Farmakologia. Elsevier Urban & Partner, Wrocław 2014: 226-231.
11. Osei-Hyiaman D., Harvey-White J., Bátkai S. et al.: The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes. (Lond.) 2006; 30(supl. 1): 33-38.
12. Begg M., Pacher P., Bátkai S. et al.: Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005; 106(2): 133-145.
13. Abadinsky H.: Drugs: An Introduction. Wyd. 5. 2004: 62-77; 160-166.
14. Pertwee R.G.: The pharmacology of cannabinoid receptors and their ligands: an overview. Int. J. Obes. 2006; 30: 13-18.
15. Hill K.P.: Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. JAMA 2015; 313: 2474-2483.
16. Ablin J., Ste-Marie P.A., Schafer M. et al.: Medical use of cannabis products. Lessons to be learned from Israel and Canada. Schmerz 2016; 30: 3-13.
17. Koppel B.S., Brust J.C., Fife T. et al.: Systematic review efficacy and safety of medical marijuana in selected neurologic disorders. Neurology 2014; 82: 1556-1563.
18. Lohr L.: Chemotherapy-induced nausea and vomiting. Cancer J. 2008; 14(2): 85-93.
19. AOTM. Sativex - stwardnienie rozsiane [online].
20. EMA. Sativex [online].
21. Talan J.: Cannabidiol research of first hope for seizure disorders. Neurology Today 2017; 17(2): 1-10.
22. Zajicek J.P., Hobart J.C., Slade A. et al.; MUSEC Research Group: Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatry 2012; 83(11): 1125-1132.
23. Zajicek J., Fox P., Sanders H. et al.; UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-1526.
24. Zajicek J., Ball S., Wright D. et al.; CUPID investigator group: Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12(9): 857-865.
25. Rog D.J., Nurmikko T.J., Friede T. et al.: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-819.
26. Svendsen K.B., Jensen T.S., Bach F.W.: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253-258.
27. Whiting P.F., Wolff R.F., Deshpande S. et al.: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA 2015; 313: 2456-2473.
28. Farrar J.T., Troxel A.B., Stott C. et al.: Validity, Reliability, and Clinical Importance of Change in a 0–10 Numeric Rating Scale Measure of Spasticity: a Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. Clin. Ther. 2008; 30(5): 974-985.
29. Anwar K., Barnes M.P.: A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation 2009; 24(4): 333-340.
30. Hawker G.A., Mian S., Kendzerska T. et al.: Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. (Hoboken) 2011; 63(supl. 11): S240-S252.
31. Wade D.T., Makela P.M., House H. et al.: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler. 2006; 12(5): 639-645.
32. Nie ma leczniczej marihuany. Medexpress [online].